Aspire Biopharma (ASBP) Stock Price, News & Analysis

Company Overview

Aspire Biopharma, Inc. is a biotechnology company focused on developing rapid drug-delivery technologies and pharmaceutical products. The company’s platform is designed to administer medications through the sublingual and buccal tissues of the mouth, with the goal of enabling faster absorption than conventional oral tablets.

Aspire Biopharma’s lead product candidate is an orally delivered, fast-acting aspirin formulation intended for potential use in cardiovascular emergencies and other situations in which rapid aspirin administration may be beneficial. The company has also described its delivery platform as potentially adaptable to other medicines, although its development programs remain subject to clinical, regulatory and commercial requirements.

The company’s operations are centered on advancing its drug-delivery platform and related product candidates through development and regulatory processes. Publicly available information provides limited detail regarding its broader geographic operations and leadership history.

Key Stats

• Today's Range: $7.80 to $8.50
• 50-Day Range: $7.04 to $9.25
• 52-Week Range: $3.31 to $562.92
• Volume: 24,582 shs
• Average Volume: 283,054 shs
• Market Capitalization: $11.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Aspire Biopharma Stock Analysis - MarketRank™

Aspire Biopharma scored higher than 15% of companies evaluated by MarketBeat, and ranked 428th out of 484 stocks in the consumer discretionary sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Aspire Biopharma has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Aspire Biopharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Aspire Biopharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aspire Biopharma is -0.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.03% of the float of Aspire Biopharma has been sold short.

Short Interest Ratio / Days to Cover

Aspire Biopharma has a short interest ratio ("days to cover") of 0.42, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aspire Biopharma has recently decreased by 60.77%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aspire Biopharma does not currently pay a dividend.

Dividend Growth

Aspire Biopharma does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.94

News Sentiment

Aspire Biopharma has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Consumer Discretionary companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aspire Biopharma this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for ASBP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aspire Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.80% of the stock of Aspire Biopharma is held by insiders.

Percentage Held by Institutions

19.17% of the stock of Aspire Biopharma is held by institutions.

Company Calendar

• Last Earnings: 11/14/2025
• Today: 10/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Discretionary
• Industry: Automobile Components
• Sub-Industry: Automotive Parts & Equipment
• Current Symbol: NASDAQ:ASBP
• Previous Symbol: NASDAQ:PWUP
• CIK: 1847345
• Web: aspirebiolabs.com
• Phone: (561) 704-8527
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($69.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.48 million
• Net Margins: -11,362.21%
• Pretax Margin: -11,361.18%
• Return on Equity: N/A
• Return on Assets: -177.59%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.99
• Quick Ratio: 7.82

Sales & Book Value

• Annual Sales: $97.66 thousand
• Price / Sales: 119.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($54.19) per share
• Price / Book: -0.15

Miscellaneous

• Outstanding Shares: 1,403,000
• Free Float: 1,322,000
• Market Cap: $11.68 million
• Optionable: N/A
• Beta: 0.17